{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:04:28Z","timestamp":1784034268745,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40273-025-01558-0","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:30:14Z","timestamp":1762950614000},"page":"233-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health-Service Costs for the Treatment of Multidrug-Resistant\/Rifampicin-Resistant Tuberculosis in South African Children: Application of a Real-World Dataset"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-2196","authenticated-orcid":false,"given":"Thomas","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"von Delft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Sinanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Simon","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1558_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2024. Geneva; 2024"},{"issue":"5","key":"1558_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.5588\/ijtld.17.0357","volume":"22","author":"HE Jenkins","year":"2018","unstructured":"Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018;22(5):S3-6.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"1558_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","volume":"19","author":"T Wilkinson","year":"2016","unstructured":"Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health. 2016;19(8):921\u20138.","journal-title":"Value Health."},{"issue":"4","key":"1558_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2989\/16085906.2019.1680398","volume":"18","author":"W DeCormier Plosky","year":"2019","unstructured":"DeCormier Plosky W, Bollinger LA, Alexander L, Cameron DB, Carroll LN, Cunnama L, et al. Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB: methodology and lessons learned. Afr J AIDS Res. 2019;18(4):263\u201376.","journal-title":"Afr J AIDS Res"},{"issue":"36","key":"1558_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2024.100449","volume":"1","author":"JT Gaensbauer","year":"2024","unstructured":"Gaensbauer JT, Dash N, Verma S, Hall DJ, Adler-Shohet FC, Li G, et al. Multidrug-resistant tuberculosis in children: a practical update on epidemiology, diagnosis, treatment and prevention. J Clin Tuberc Other Mycobact Dis. 2024;1(36):100449.","journal-title":"J Clin Tuberc Other Mycobact Dis."},{"key":"1558_CR6","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva; 2022."},{"issue":"8","key":"1558_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12098-023-04888-z","volume":"91","author":"HS Schaaf","year":"2024","unstructured":"Schaaf HS, Hughes J. Current treatment of drug-resistant tuberculosis in children. Indian J Pediatr. 2024;91(8):806\u201316.","journal-title":"Indian J Pediatr"},{"key":"1558_CR8","unstructured":"The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of drug-resistant tuberculosis in children: a field guide (fifth edition). Boston; 2022."},{"issue":"3","key":"1558_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3201\/eid2703.203204","volume":"27","author":"SV Leavitt","year":"2021","unstructured":"Leavitt SV, Jacobson KR, Ragan EJ, Bor J, Hughes J, Bouton TC, et al. Decentralized care for rifampin-resistant tuberculosis, Western Cape, South Africa. Emerg Infect Dis. 2021;27(3):728\u201339.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"1558_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5588\/ijtld.21.0538","volume":"26","author":"HK Musonda","year":"2022","unstructured":"Musonda HK, Rose PC, Switala J, Schaaf HS. Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes. Int J Tuberc Lung Dis. 2022;26(3):217\u201323.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1558_CR11","first-page":"19","volume":"1","author":"T Wilkinson","year":"2024","unstructured":"Wilkinson T, Garcia-Prats AJ, Sachs T, Paradkar M, Suryavanshi N, Kinikar A, et al. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines. PLoS ONE. 2024;1:19.","journal-title":"PLoS ONE"},{"key":"1558_CR12","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment, 2022 update. Geneva; 2022."},{"key":"1558_CR13","unstructured":"South African Department of Health. Management of rifampicin-resistant tuberculosis: a clinical reference guide. Pretoria; 2019."},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hec.3295","volume":"25","author":"L Cunnama","year":"2016","unstructured":"Cunnama L, Sinanovic E, Ramma L, Foster N, Berrie L, Stevens W, et al. Using top-down and bottom-up costing approaches in LMICs: the case for using both to assess the incremental costs of new technologies at scale. Health Econ. 2016;25:53\u201366.","journal-title":"Health Econ"},{"issue":"8","key":"1558_CR15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40273-020-00910-w","volume":"38","author":"L Cunnama","year":"2020","unstructured":"Cunnama L, Gomez GB, Siapka M, Herzel B, Hill J, Kairu A, et al. A systematic review of methodological variation in healthcare provider perspective tuberculosis costing papers conducted in low- and middle-income settings, using an intervention-standardised unit cost typology. Pharmacoeconomics. 2020;38(8):819\u201337.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1558_CR16","doi-asserted-by":"publisher","first-page":"e1034","DOI":"10.1016\/S2214-109X(22)00113-9","volume":"10","author":"PJ Dodd","year":"2022","unstructured":"Dodd PJ, Mafirakureva N, Seddon JA, McQuaid CF. The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study. Lancet Glob Health. 2022;10(7):e1034\u201344.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/tmi.12544","volume":"20","author":"H Cox","year":"2015","unstructured":"Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa. Trop Med Int Health. 2015;20(10):1337\u201345.","journal-title":"Trop Med Int Health"},{"issue":"5","key":"1558_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2471\/BLT.19.243584","volume":"98","author":"JJ Madan","year":"2020","unstructured":"Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the stream trial. Bull World Health Organ. 2020;98(5):306\u201314.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"1558_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/thoraxjnl-2011-200933","volume":"68","author":"AM Mandalakas","year":"2013","unstructured":"Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax. 2013;68(3):247\u201355.","journal-title":"Thorax"},{"issue":"2","key":"1558_CR20","first-page":"06","volume":"4","author":"A Boulle","year":"2019","unstructured":"Boulle A, Heekes A, Tiffin N, Smith M, Mutemaringa T, Zinyakatire N, et al. Data centre profile: the provincial health data centre of the Western Cape Province, South Africa. Int J Popul Data Sci. 2019;4(2):06.","journal-title":"Int J Popul Data Sci."},{"issue":"1","key":"1558_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5588\/pha.20.0031","volume":"11","author":"R Manesen","year":"2021","unstructured":"Manesen R, Mekler KA, Molobi TR, Tyiki AA, Madlavu MJ, Velen K, et al. Data quality assessment of a South African electronic registry for drug-resistant TB, 2015\u20132016. Public Health Action. 2021;11(1):33.","journal-title":"Public Health Action."},{"key":"1558_CR22","unstructured":"National Department of Health. Uniform Patient Fee Schedule\u2014April 2021 [Internet]. Pretoria; 2021. https:\/\/www.health.gov.za\/uniform-patient-fee-schedule\/."},{"key":"1558_CR23","unstructured":"National Health Laboratory Service. NHLS State price list 2021. Pretoria; 2021."},{"key":"1558_CR24","unstructured":"National Department of Health; Republic of South Africa. Master Health Product List\u2014March 2021 [Internet]. Pretoria; 2021. https:\/\/www.health.gov.za\/tenders\/."},{"issue":"2","key":"1558_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5588\/ijtld.14.0421","volume":"19","author":"E Sinanovic","year":"2015","unstructured":"Sinanovic E, Ramma L, Vassall A, Azevedo V, Wilkinson L, Ndjeka N, et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015;19(2):172\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"1558_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196003","volume":"13","author":"M Loveday","year":"2018","unstructured":"Loveday M, Wallengren K, Reddy T, Besada D, Brust JCM, Voce A, et al. MDR-TB patients in KwaZulu-Natal, South Africa: cost-effectiveness of 5 models of care. PLoS ONE. 2018;13(4):e0196003.","journal-title":"PLoS ONE"},{"issue":"1","key":"1558_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11595340-000000000-00000","volume":"30","author":"C Fitzpatrick","year":"2012","unstructured":"Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63\u201380.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1558_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.5588\/ijtld.19.0694","volume":"24","author":"M Siapka","year":"2020","unstructured":"Siapka M, Vassall A, Cunnama L, Pineda C, Cerecero D, Sweeney S, et al. Cost of tuberculosis treatment in low-and middle-income countries: systematic review and meta-regression. Int J Tuberc Lung Dis. 2020;24(8):802\u201310.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"1558_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/INF.0000000000002631","volume":"39","author":"HS Schaaf","year":"2020","unstructured":"Schaaf HS, Garcia-Prats AJ, Draper HR, Rautenbach C, Bosch C, Demers AM, et al. Trends in drug resistance in childhood tuberculosis in Cape Town, South Africa. Pediatr Infect Dis. 2020;39(7):604\u20138.","journal-title":"Pediatr Infect Dis"},{"issue":"2","key":"1558_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B\u20133, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117\u201328.","journal-title":"Lancet Respir Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01558-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:35:19Z","timestamp":1769783719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01558-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01558-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data produced in the study beyond that presented in the Electronic Supplementary Material are available upon reasonable request to the authors and on approval of the Provincial Health Data Centre of the Western Cape Government Department of Health and Wellness, South Africa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"TW led study conceptualisation and design with contribution from all authors. Material preparation, data collection and analysis were performed by TW with support from JAS. The first draft of the manuscript was written by TW and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}